Decision making about infertility treatment: does unlimited access lead to inappropriate treatment? by unknown
COMMENTARY Open Access
Decision making about infertility treatment:




The proportion of women aged 40–44 undergoing IVF treatment covered by Maccabi Health Services increased
between 2011 and 2014. Although age-specific birth rates did not substantially change over this time period, the
demographic change was accompanied by an overall decrease in live births after IVF treatment. The relative
contribution of changing population demographics vs. current age-related coverage policies to these trends is
unclear. Additional research is needed to better understand the potential effect of changes in current policy on
maternal, neonatal, and economic outcomes.
Background
Economic incentives and disincentives clearly play a role
in couples’ decision making about having children. In
the United States, birth rates declined during the Great
Recession, with declines greatest in those states most
affected by job loss [1]. Studies from Israel suggest that
policies and practices affecting the level of child support
are strongly correlated with birth rates [2, 3]. Not sur-
prisingly, couples are more likely to try to have children
when there is greater certainty that the resources needed
to raise those children will be available.
For couples who are unable to spontaneously conceive,
there is an additional consideration—the resources needed
to undergo diagnosis and treatment of infertility. Again,
there is evidence that infertility services are more likely to
be utilized when those resources are at least partly covered
by private or government insurance. Utilization of assisted
reproductive technology (ART) varies between states in the
U.S., with utilization greater in states where there is a legal
mandate for insurers to provide coverage [4–6]. Increasing
access in this way may have some beneficial effects—if the
costs of multiple cycles is lower, couples may be less in-
clined to opt for more aggressive per-cycle treatment (such
as replacement of multiple embryos) [4–6], which, while
increasing the per-cycle success rate, also increases the
probability of multiple gestations, with accompanying in-
creased risk for maternal complications, preterm birth, and
short- and long-term morbidity in the offspring.
Although there are a number of causes of infertility, a
substantial proportion of couples will have no identifiable
underlying pathological diagnosis; for many of these
couples, the most likely reason for a decline in fecundity is
the age-related decline in ovarian function in women.
“Older” women make up an increasing proportion of the
infertility population in many centers [7]; success rates in
the absence of the use of donor oocytes in this population
are substantially lower than for younger women [8].
Commentary on Kol et al. [9]
In a recent IJHPR article, Kol and colleagues report on
trends in the utilization and outcomes of in vitro
fertilization (IVF) from 2007–2014 within the Maccabi
Healthcare Services, which cover approximately 25 % of
the Israeli population. The key findings of their report are:
 The total number of treatments increased from 2007
to 2011, with a subsequent decrease afterwards; this
was accompanied by a decrease in overall live birth.
 The age distribution of the population undergoing
IVF treatment changed from 2011–2014, with the
proportion of women 25–39 (those with the highest
success rates) declining from 67 to 57.6 %.Correspondence: evan.myers@duke.edu
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 Age-specific success rates, defined as live births
divided by number of IVF cycles, were fairly
consistent from year-to-year (Table 2 in Kol et al.).
 Live birth rates per cycle and per patient declined
from 2007 to 2014, in parallel with the change in
the demographics of the population.
 There is substantial variability in live birth rates
between centers, although data on patient
demographics and clinical aspects of treatment are
not presented.
These data suggest that the overall decline in live birth
rates observed in the population covered by Maccabi
Healthcare Services is largely attributable to an increase in
the proportion of IVF patients where the female partner is
40 or older. The authors attribute this phenomenon to
Ministry of Health policy allowing relatively unrestricted
access to multiple IVF treatments for women under the
age of 45, leading to exceptionally high rates of IVF on a
population-basis, but overall success rates substantially
lower than the rest of the developed world [9].
Although the authors’ speculation about the relationship
between unrestricted access to IVF and the observed out-
comes is certainly plausible, there are some other factors to
consider, especially with respect to this particular data set.
Although Maccabi Healthcare Services represents
25 % of the female Israeli population in the reproductive
age groups [9], it is not necessarily the case that the rele-
vant characteristics of this population in terms of age,
distribution of infertility diagnoses, income, or other fac-
tors contributing to utilization and outcomes of infertil-
ity services are representative of the entire Israeli
population. At the very least, it would be helpful to
know how the age distribution compares to that of the
overall Israeli population.
Second, it would be very helpful to know the population-
based rate of IVF utilization, rather than just the raw num-
bers of cycles. Other countries, including those where
coverage is much more variable, are also observing in-
creased utilization of infertility services by older women
[7]; some of the increase in raw numbers of treatments in
older women may simply be attributable to increased num-
bers of older women, along with cohort effects associated
with delayed childbearing. The argument that unlimited
access to IVF treatment for older women with poor prog-
nosis is an inefficient use of resources is an important one
to make, but it would be useful to understand the extent to
which increased numbers of IVF cycles in older women are
due to changes in the numerator of the age-specific rate
(increasing numbers of procedures among women in the
40–44 year age group for a given number of women in that
age group), or in the denominator (similar numbers of pro-
cedures in women 40–44 for a given number of women in
that age group, but the total number of women in the age
group has increased). If nothing else, better understanding
of the relationship between demand for services and the
underlying demographics of the patient population would
be useful for making estimates of the impact of changes in
policy on IVF-related outcomes.
Third, there is a growing consensus that the most ap-
propriate outcome for assessing the effectiveness of in-
fertility treatment is the cumulative live birth rate per
couple over time [10], which may result in much differ-
ent conclusions compared to per cycle success rates.
The data presented in the paper by Kol and colleagues
make it difficult to draw conclusions about this metric.
Although it is possible to calculate live births per couple
treated, the distribution of the number of treatments per
couple is not presented. In addition, it would be very
helpful for the purposes of policy analysis to know
whether decreased success rates in older women were
also accompanied by increases in complications of treat-
ment, or in increased rates of maternal or neonatal com-
plications of pregnancy. Women 40 and older who have
undergone infertility treatment are at increased risk for
a number of complications, even with singleton preg-
nancies, although use of donor oocytes seems to elimin-
ate most of this risk [8]. While the economic argument
against unlimited access to treatments with a low prob-
ability of success is compelling, it would be even stron-
ger if there were evidence that unrestricted access was
leading to increased harms to mothers and infants.
Conclusions
During the past five years, the proportion of IVF treat-
ments provided by the Maccabi Healthcare Services to
women aged 40–44 has increased substantially, which
has been accompanied by an overall decrease in success
rates per treatment cycle. The extent to which current
Israeli Ministry of Health policies regarding age restric-
tions on IVF treatment are responsible for this observa-
tion, as opposed to changes in the underlying patient
demographics, is unclear. Potential changes in coverage
policies should consider estimates of the size of the po-
tential patient population, trends in the epidemiology of
different causes of infertility, both benefits (cumulative
live birth per couple) and harms (maternal and neonatal
complications) of IVF treatment in women of different
age groups, and the economic impact of these policies.
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